Caxton Associates LLP Purchases New Holdings in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Caxton Associates LLP has acquired a new stake in Amneal Pharmaceuticals, purchasing 40,440 shares valued at approximately $339,000.
• Institutional investors now own 31.82% of Amneal Pharmaceuticals, with significant increases in holdings by firms such as GAMMA Investing LLC and Amalgamated Bank.
• Analysts maintain a consensus Buy rating for Amneal Pharmaceuticals, with a price target averaging $11.60.

Caxton Associates LLP purchased a new position in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,440 shares of the company's stock, valued at approximately $339,000.

Several other hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of AMNEAL PHARMACEUTICALS by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after purchasing an additional 3,107 shares in the last quarter. Headlands Technologies LLC acquired a new position in AMNEAL PHARMACEUTICALS during the first quarter worth about $31,000. Amalgamated Bank boosted its stake in shares of AMNEAL PHARMACEUTICALS by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in AMNEAL PHARMACEUTICALS in the fourth quarter valued at approximately $52,000. Finally, Xponance Inc. boosted its holdings in shares of AMNEAL PHARMACEUTICALS by 16.1% during the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after acquiring an additional 1,828 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

AMNEAL PHARMACEUTICALS Stock Performance

Shares of NASDAQ AMRX traded down $0.21 during midday trading on Monday, hitting $9.79. 1,377,949 shares of the stock traded hands, compared to its average volume of 1,434,951. AMNEAL PHARMACEUTICALS, INC. has a one year low of $6.68 and a one year high of $10.34. The business has a 50 day moving average price of $8.86 and a two-hundred day moving average price of $8.19. The company has a market cap of $3.07 billion, a PE ratio of 979.98 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $11.60.

Insider Buying and Selling

In related news, EVP Jason B. Daly sold 22,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Kiely sold 32,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total transaction of $295,360.00. Following the transaction, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This represents a 12.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 609,206 shares of company stock valued at $5,700,625. 17.45% of the stock is owned by company insiders.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.